Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Standard Biotools Inc - SIC # 3826 - LABORATORY ANALYTICAL INSTRUMENTS
Ticker
Exchange
SIC #
Website
Latest Ticker
LAB
Nasdaq
3826
https://www.fluidigm.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Standard Biotools Inc
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Mar 22nd, 2023 12:30 pm
Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors
- Mar 15th, 2023 12:30 pm
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
- Mar 14th, 2023 12:30 pm
Standard BioTools to Present at 43rd Annual Cowen Health Care Conference
- Mar 1st, 2023 9:05 pm
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 21st, 2023 1:30 pm
Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript
- Feb 17th, 2023 11:43 pm
How a Peninsula biotech tools company looks to corral 'one-trick ponies'
- Feb 15th, 2023 11:01 pm
Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook
- Feb 14th, 2023 9:05 pm
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable
- Feb 3rd, 2023 10:30 am
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results
- Jan 31st, 2023 1:30 pm
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
- Jan 9th, 2023 1:30 pm
Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer
- Jan 3rd, 2023 1:30 pm
Standard BioTools Inc. (NASDAQ:LAB) institutional owners may be pleased with recent gains after 64% loss over the past year
- Dec 24th, 2022 1:01 pm
Standard BioTools Authorizes up to $20 Million of Share Repurchases
- Nov 28th, 2022 1:30 pm
Standard BioTools Third Quarter 2022 Earnings: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021)
- Nov 11th, 2022 10:02 am
Standard BioTools Announces Third Quarter 2022 Financial Results
- Nov 8th, 2022 9:05 pm
Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems
- Nov 7th, 2022 9:05 pm
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
- Oct 25th, 2022 12:30 pm
Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China
- Oct 13th, 2022 12:30 pm
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
- Oct 6th, 2022 12:30 pm
Scroll